SEEK concludes HIV-v vaccine Phase Ib/II trial
UK based biopharmaceutical firm SEEK has concluded a Phase Ib/II trial evaluating the safety, efficacy and tolerability of HIV-v vaccine.
The vaccine showed almost 90% difference in viral count in HIV-infected patients in comparison to placebo group, following a single vaccine injection.
SEEK claims its HIV-v vaccine targets only the conserved regions in the internal proteins of the HIV virus which remain constant across all HIV strains.
The company expects to investigate partnerships to undertake complete human trials during 2012-13.
SEEK CEO Gregory Stoloff said the next step will be to progress this to final human trials and determine the optimum dose and dosing regime to further enhance the vaccine's efficacy.
SEEK chief scientific officer Wilson Caparros Wanderley said the results demonstrate that after a single immunizationthe HIV-v vaccine produces a response from both the antibody and T cell immune systems to the conserved regions only.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $0